Related Experiment Videos
Coagulation abnormalities and ivermectin
J A Whitworth1, C R Hay, A M McNicholas
1Medical Research Council Laboratory, Sierra Leone.
Abstract:
Prothrombin ratios were measured 13-16 days after treatment in 148 subjects from Sierra Leone taking part in a double-blind placebo-controlled trial of ivermectin. Prolonged prothrombin ratios were observed more frequently in the ivermectin group, although this difference was not significant and no patients suffered bleeding complications. Further investigation of these patients failed to reveal any abnormality of liver function, although factor VII and II levels were reduced in most affected individuals, suggesting interference with vitamin K metabolism. Ivermectin has a minimal effect on coagulation and concern about mass treatment for this reason appears to be unjustified.
Insights
Ivermectin treatment showed a slight, non-significant increase in prothrombin ratios in Sierra Leone subjects. No bleeding occurred, suggesting ivermectin has minimal impact on blood coagulation for mass treatment programs.
Area of Science:
- Pharmacology
- Hematology
- Tropical Medicine
Background:
- Ivermectin is widely used for treating parasitic infections.
- Concerns exist regarding potential effects of ivermectin on blood coagulation.
- Understanding ivermectin's impact on coagulation is crucial for public health initiatives.
Purpose of the Study:
- To assess the effect of ivermectin on prothrombin ratios in subjects from Sierra Leone.
- To investigate potential interference with vitamin K metabolism and liver function.
- To evaluate the safety of ivermectin regarding coagulation for mass treatment.
Main Methods:
- A double-blind, placebo-controlled trial involving 148 subjects.
- Measurement of prothrombin ratios 13-16 days post-treatment.
- Investigation of liver function and coagulation factor levels (VII and II).
Main Results:
- Prolonged prothrombin ratios were observed more frequently in the ivermectin group, but the difference was not statistically significant.
- No bleeding complications were reported in any patients.
- Reduced levels of coagulation factors VII and II were noted in affected individuals, suggesting potential vitamin K metabolism interference.
- No abnormalities in liver function tests were detected.
Conclusions:
- Ivermectin demonstrates a minimal effect on blood coagulation.
- Concerns regarding ivermectin's impact on coagulation for mass treatment appear to be unwarranted.
- Further investigation into vitamin K metabolism may be warranted for specific patient groups.